Oruka Therapeutics, Inc. (ORKA) Key Metrics
ORKA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.76B
- Enterprise value
- $5.08B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 5.4 10-yr median 7.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.11
ORKA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsORKA valuation Price multiples at each fiscal year-end price.
ORKA returns How much profit the business earns on the capital it uses.
ORKA per-share figures Results divided by the shares outstanding at year-end.
ORKA financial health Debt, liquidity and how easily interest is covered.
ORKA efficiency & capital use Working capital cycle and where the cash goes.
ORKA valuation history
ORKA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ORKA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ORKA price vs earnings per share
ORKA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.38B | $325.5M | $294.1M | $409.8M | $358.7M | — | — | — | — | — |
| Enterprise value | $1.05B | −$49.1M | $256.9M | $367.8M | $305.8M | — | — | — | — | — |
| Price / book | 2.9 | 0.9 | 7.9 | 9.8 | 7.0 | — | — | — | — | — |
| Earnings yield | −7.6% | −25.7% | −1.8% | −2.4% | −5.4% | — | — | — | — | — |
| Free cash flow yield | −6.4% | −17.8% | — | −2.7% | −5.2% | — | — | — | — | — |
| Share price at fiscal year-end | $30.31 | $19.39 | $20.40 | $28.44 | $25.80 | $48.12 | $68.52 | $71.28 | $291.60 | $615.60 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$2.31 | −$4.99 | −$0.37 | −$0.69 | −$1.39 | — | — | — | — | — |
| Operating cash flow per share | −$1.93 | −$3.44 | — | −$0.76 | −$1.35 | — | — | — | — | — |
| Free cash flow per share | −$1.94 | −$3.46 | — | −$0.76 | −$1.35 | — | — | — | — | — |
| Cash per share | $7.39 | $22.37 | $2.60 | $2.95 | $3.84 | — | — | — | — | — |
| Book value per share | $10.35 | $22.77 | $2.57 | $2.89 | $3.67 | — | — | — | — | — |
| Tangible book value per share | $10.35 | $22.77 | $2.57 | $2.89 | $3.67 | — | — | — | — | — |
| Capex per share | $0.00 | $0.01 | — | $0.00 | $0.00 | — | — | — | — | — |
| Debt per share | $0.04 | $0.06 | $0.02 | $0.03 | $0.03 | — | — | — | — | — |
| Shares outstanding | 45.6M | 16.8M | 14.4M | 14.4M | 13.9M | — | — | — | — | — |
| Change in shares outstanding | +171.7% | +16.5% | +0.0% | +3.6% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −24.7% | −39.9% | −13.6% | −21.4% | −39.6% | −36.0% | −80.4% | −97.3% | −113.9% | −54.6% |
| Return on invested capital (ROIC) | −133.6% | — | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −23.8% | −38.6% | −13.2% | −20.3% | −36.7% | −33.0% | −71.4% | −82.7% | −100.0% | −51.2% |
| Return on tangible assets | −21.6% | −21.1% | −14.1% | −23.0% | −35.2% | −19.3% | −64.2% | −116.2% | −149.5% | −66.8% |
| Financial health | ||||||||||
| Total debt | $1.9M | $968,000 | $280,000 | $383,000 | $483,000 | $450,000 | $25,000 | — | — | — |
| Cash & short-term investments | $337.0M | $375.6M | $37.4M | $42.4M | $53.4M | $49.1M | $8.4M | $6.6M | $11.8M | $21.2M |
| Net debt | −$335.1M | −$374.7M | −$37.2M | −$42.1M | −$52.9M | −$48.6M | −$8.3M | −$6.6M | −$11.8M | −$21.2M |
| Debt / equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | — | — | — |
| Current ratio | 22.37 | 28.89 | 59.01 | 37.72 | 15.56 | 14.28 | 9.16 | 8.55 | 5.94 | 8.95 |
| Quick ratio | 22.37 | 28.89 | 59.01 | 37.72 | 15.56 | 14.28 | 9.16 | 8.55 | 5.94 | 8.95 |
| Interest coverage | — | -60.0 | — | — | — | — | -830.6 | — | — | — |
| Working capital | $328.5M | $363.8M | $37.0M | $41.6M | $50.9M | $46.5M | $7.6M | $6.0M | $10.2M | $19.0M |
| Invested capital | $136.8M | $7.5M | −$131,000 | −$389,000 | −$1.8M | −$2.1M | −$728,000 | −$576,000 | −$1.5M | $1.0M |
| Tangible asset value | $471.9M | $382.2M | $37.0M | $41.7M | $51.0M | $46.5M | $7.6M | $6.0M | $10.3M | $22.2M |
| Net current asset value | $327.2M | $363.1M | $36.8M | $41.3M | $50.5M | $46.1M | $7.6M | $6.0M | $10.2M | $19.0M |
| Graham net-net per share | $7.02 | $21.55 | $2.54 | $2.85 | $3.56 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / depreciation | 2.52 | 7.00 | — | 0.02 | 0.47 | 0.20 | 0.04 | 0.18 | 0.11 | 0.50 |
| Efficiency | ||||||||||
| Days payables outstanding | 16,748.2 | 46,801.1 | — | 2,322.9 | 5,795.9 | 4,299.5 | 1,328.8 | 7,067.7 | 8,408.5 | — |
| Payables turnover | 0.02 | 0.01 | — | 0.16 | 0.06 | 0.08 | 0.27 | 0.05 | 0.04 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $3.8M | $3.5M | — | $725,500 | $1.4M | $1.1M | $324,000 | $426,000 | $622,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ORKA's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ORKA valuation and financial ratios
Oruka Therapeutics earned a return on equity of −24.7% and a return on invested capital of −133.6% in fiscal 2025. It ended the year with $1.9 million of debt and $337.0 million in cash and short-term investments, a net cash position of $335.1 million.
See the ORKA income statement, the ORKA chart for price history, or the ORKA stock overview for the latest quote and news.
ORKA key metrics FAQ
What is Oruka Therapeutics's return on equity?
Oruka Therapeutics's return on equity (ROE) was −24.7% in fiscal 2025: net income of -$105.4 million on average shareholders' equity of $427.1 million.
What is Oruka Therapeutics's ROIC?
Oruka Therapeutics's return on invested capital was −133.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Oruka Therapeutics have?
Oruka Therapeutics had total debt of $1.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Oruka Therapeutics's free cash flow yield?
Oruka Therapeutics generated -$88.4 million of free cash flow in fiscal 2025, a free cash flow yield of −6.4% on its market value at year-end ($1.4 billion).
What is Oruka Therapeutics's current ratio?
Oruka Therapeutics's current ratio was 22.37 at the end of fiscal 2025: current assets were 22.37 times current liabilities.